Actively Recruiting
Myocardial Work Evaluation in Patients With PAH
Led by Central Hospital, Nancy, France · Updated on 2024-08-28
30
Participants Needed
1
Research Sites
9 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Right ventricular function is a key determinant of survival in patients with pulmonary arterial hypertension, with right heart failure being the leading cause of death. ERS/ESC guidelines recommend evaluating RV function at diagnosis and at first reevaluation under treatment to estimate the one-year mortality risk. However, few RV function markers address both systolic function and afterload. Noninvasive myocardial work is a promising new tool that incorporates systolic function and its afterload into global longitudinal strain. Initially developed for the left ventricle, it can be adapted for the RV using pressure-strain loops. The article aims to evaluate the association of RV myocardial work parameters with the estimate one-year mortality in patients with PAH. This retrospective study will include patients diagnosed with PAH with transthoracic echocardiography and right heart catheterization within 48 hours at diagnosis and first reevaluation. Patients with unanalyzable echocardiography data will be excluded.
CONDITIONS
Official Title
Myocardial Work Evaluation in Patients With PAH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All consecutive incident patients diagnosed with idiopathic, heritable, drug-associated pulmonary hypertension, or pulmonary hypertension associated with portal hypertension referred to the PH reference center at Nancy university hospital
- Underwent transthoracic echocardiography and right heart catheterization within 48 hours at diagnosis and at first reevaluation with PAH treatment
You will not qualify if you...
- Cardiac ultrasound data not analyzable due to poor echogenicity or poor quality of right ventricular images
- Pulmonary hypertension associated with left-heart disease (group 2)
- Pulmonary hypertension associated with lung diseases and/or hypoxia (group 3)
- Pulmonary hypertension associated with pulmonary artery obstructions (group 4)
- Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)
- Positive response to vasoreactivity test or features of venous or capillary involvement
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Valentin
Nancy, France
Actively Recruiting
Research Team
S
Simon Valentin, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here